ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
2seventy bio Inc

2seventy bio Inc (TSVT)

4.79
0.22
(4.81%)
Closed July 28 4:00PM
4.81
0.02
(0.42%)
After Hours: 6:40PM

Calls

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.500.000.000.000.000.000.00 %00-
5.000.150.750.750.450.3066.67 %92037/26/2024

Empower your portfolio: Real-time discussions and actionable trading ideas.

Puts

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.500.000.000.000.000.000.00 %00-
5.000.000.000.000.000.000.00 %00-

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WINTWindtree Therapeutics Inc
$ 8.24
(150.46%)
48.57M
BFIBurgerFi International Inc
$ 0.4206
(97.37%)
313.59M
NBSTWNewbury Street Acquisition Corporation
$ 0.1349
(92.71%)
122.1k
YIBOPlanet Image International Ltd
$ 2.915
(53.43%)
260.07k
CREVCarbon Revolution Public Ltd
$ 9.00
(45.87%)
8.06M
NMHINatures Miracle Holding Inc
$ 0.2035
(-48.06%)
7.69M
TANHTantech Holdings Ltd
$ 0.2585
(-47.23%)
6.75M
DXCMDexCom Inc
$ 64.00
(-40.66%)
53.92M
PSIGPS International Group Ltd
$ 1.42
(-31.40%)
716.26k
POAIPredictive Oncology Inc
$ 1.36
(-27.27%)
6.02M
SLNASelina Hospitality PLC
$ 0.0305
(-18.88%)
408.61M
BFIBurgerFi International Inc
$ 0.4206
(97.37%)
313.59M
NVDANVIDIA Corporation
$ 113.06
(0.69%)
293.33M
SQQQProShares UltraPro Short QQQ
$ 9.10
(-2.88%)
176.49M
SGMOSangamo Therapeutics Inc
$ 0.8612
(28.15%)
123.71M

TSVT Discussion

View Posts
Monksdream Monksdream 3 months ago
TSVT under $5
👍️0
Invest-in-America Invest-in-America 4 months ago
TSVT: Big (Post-M) news for this Firm & partner Bristol Myers.

"Bristol Myers, 2seventy Bios Cancer Treatment Wins FDA Committee Approval
7:04 PM ET 3/15/24 | Dow Jones
By Ben Glickman Bristol Myers Squibb and 2seventy Bio's cancer treatment showed a favorable risk-benefit profile in certain populations, according to Food and Drug Administration committee. The Oncologic Drugs Advisory Committee voted 8-3 that Abecma, a gene therapy, had a favorable profile in the treatment of the blood cancer multiple myeloma, specifically in the triple-class exposed relapsed or refractory forms of the cancer, the companies said on Friday. Bristol Myers Squibb and 2seventy said the recommendation would be considered by the FDA in its review of their supplemental Biologics License Application. The FDA hasn't assigned a new target action date for reviewing that application, the companies said. Abecma was recently approved in Japan and Switzerland for patients with relapsed or refractory multiple myeloma who have received at least two prior therapies. Write to Ben Glickman at ben.glickman@wsj.com > Dow Jones Newswires March 15, 2024 19:04 ET (23:04 GMT)"
👍️0
Monksdream Monksdream 5 months ago
TSVT 10Q due March 5
👍️0
molee molee 6 months ago
$TSVT > A bit of "short covering" going on now ... How high ???
👍️0
Monksdream Monksdream 7 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👎️ 1 💩 1 🤡 1
johnhancoque johnhancoque 8 months ago
2 seventy will be auctioned off in Bankruptcy court within a year. Cash on hand is 12 months or less.
👍️0
molee molee 9 months ago
C'mon man . What the heck . $2.00 now ? Really ?
👍️0